EUROFINS
Eurofins Technologies (Paris:ERF), a supplier of test kits and systems for laboratory analyses, announces the launch of its new RapidScan ST5-W lateral flow reader , specifically designed for field and in-process testing applications requiring qualitative to semi-quantitative test results.
This portable instrument is a highly flexible, easy to use and accurate imaging platform used for lateral flow assay analysis. RapidScan ST5-W is unique to the market with its flexibility, multiple target analysis and its compatibility with applications for Eurofins Technologies’ allergen, GMO, glyphosate and algal toxins lateral flow tests. The reader performs well both in laboratories and in field testing environments, where quick results are needed for contamination analysis. With a data storage capacity of up to 5000 test results, reports are easy to create and export.
A wide range of Eurofins Technologies’ rapid test applications are already validated on the RapidScan reader, including gluten (allergen), corn, soybean and canola (GMO), glyphosate (pesticide) and algal toxins (toxins in drinking and fresh water) lateral flow assays. Further test validations will follow in 2022, including more than 20 allergens and additional GMO rapid testing capability.
This new reader will play an instrumental role in Eurofins Technologies’ mission to provide an integrated solution to its food and water safety customers. The reader provides a reliable and quick way to test for multiple contaminations with high-quality lateral flow devices and obtain and analyse results with a single reader platform at any environment and within just a few minutes.
About Eurofins Technologies
Building on the experience and scientific excellence of the Eurofins Group, Eurofins Technologies is a fast-growing global provider of diagnostic technologies and instruments in the field of bioanalytical testing for the food, feed, environmental, animal health, and clinical diagnostics industries.
Its R&D teams located at various sites around the world share their expertise in developing a wide range of innovative methods and applications. For further information, please visit the Eurofins Technologies website.
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. With 55,000 staff across a network of 900 laboratories in over 50 countries, Eurofins’ companies offer a portfolio of over 200,000 analytical methods.
Eurofins Shares are listed on Euronext Paris Stock Exchange.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211213005046/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rimini Street Delivers First 20 Rimini Agentic UX™ Solutions That Solve a Variety of ERP Process Challenges Faster, Better and Cheaper with Agentic AI ERP22.1.2026 15:00:00 CET | Press release
Rimini Agentic UX™ Solutions, Powered by ServiceNow®, deliver enhanced productivity, greater agility and reduced operating cost while being quick, easy and economical to deploy over the top of existing ERP Software releases without any required upgrades or migrations Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™, and the leading third-party support provider for Oracle, SAP and VMware software, today announced the immediate availability of its first 20 innovative Rimini Agentic UX™ Solutions, Powered by ServiceNow®. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260122013155/en/ Rimini Street Delivers First 20 Rimini Agentic UX™ Solutions That Solve a Variety of ERP Process Challenges Faster, Better and Cheaper with Agentic AI ERP Solving Real Business Challenges Now with Agentic AI ERP Rimini Agentic UX Solutions are already in production and helping organizations achieve better busines
LoungePair Brings on Former LoungeBuddy CEO, Enters Agreements with Vietnam Airlines, Auckland Airport22.1.2026 15:00:00 CET | Press release
Travel-tech company LoungePair has brought on LoungeBuddy founder and former American Express executive Tyler Dikman as a key advisor. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260122515067/en/ Tyler Dikman, joins LoungePair as Key Advisor The company has also signed a key partnership with Vietnam Airlines to power its new Lotusmiles Lounges platform and has added Auckland Airport's Strata Lounge to its network. LoungePair provides on-demand and walk-up airport lounge access without the need for additional memberships, reward programmes, or loyalty status. Travel Tech Expert Tyler Dikman Joins as Advisor Tyler Dikman is the co-founder and former CEO of LoungeBuddy, the airport lounge booking platform acquired by American Express in 2019. Following the acquisition, he served as Vice President of Global Premium Products and Benefits at American Express, leading the integration of LoungeBuddy and helping shape travel exper
Lone Star Acquires Alliance Ground International22.1.2026 14:55:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire Alliance Ground International (“AGI”), a leading North American airport services provider, from Greenbriar Equity Group and Audax Private Equity. Financial terms of the transaction were not disclosed. Founded in 1987 and headquartered in Miami, AGI operates in over 60 airports in North America with a workforce of more than 12,000 professionals. The company provides mission-critical, outsourced services that enable the efficient movement of cargo and passenger aircraft through major airport hubs. AGI’s core business is air cargo handling, supported by passenger terminal, ground handling and other related services. Its integrated service offering, strategic on-airport footprint and long-standing customer relationships position AGI as a trusted partner to cargo carriers and passenger airlines, supporting airport operations and global trade flows. L
Andersen Consulting konsoliderer sit udbud inden for digital transformation med tilføjelsen af Internet & Idee22.1.2026 14:04:00 CET | Pressemeddelelse
Andersen Consulting indgår en samarbejdsaftale med Internet & Idee, et italiensk digitalt konsulentbureau, og styrker dermed sin evne til at levere integrerede, teknologidrevne løsninger. Internet & Idee blev stiftet i 1998 og specialiserer sig i digital strategi, softwareudvikling, test og kvalitetssikring, e-handel og mobile løsninger. Virksomheden opererer inden for to kerneområder: It-konsulentydelser og egne SaaS-produkter, herunder værktøjer til kreditstyring og cybersikkerhed. Med dyb ekspertise inden for bankvæsen, forsikring, kreditstyring og logistik for e-handel kombinerer Internet & Idee brancheindsigt med teknisk innovation med henblik på at drive forretningsresultater. "Dette samarbejde giver os mulighed for at anvende vores digitale ekspertise og branchekendskab i større skala," udtaler Carlo Stumpo, administrerende direktør for Internet & Idee. "Sammen med Andersen Consulting kan vi levere mere målrettede og effektive løsninger til kunder, der står over for komplekse ud
Overall Survival Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer22.1.2026 14:00:00 CET | Press release
Data demonstrate a 35 percent reduction in the risk of death Both dual primary endpoints (progression-free and overall survival) were met, without the need for biomarker selection and without increased safety burden Relacorilant’s New Drug Application (NDA) is under review by the U.S. Food and Drug Administration (FDA) as a treatment for patients with platinum-resistant ovarian cancer with a Prescription Drug User Fee Act (PDUFA) target action date of July 11, 2026 Relacorilant’s Marketing Authorization Application (MAA) for patients with platinum-resistant ovarian cancer is also under review by the European Medicines Agency (EMA) Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that ROSELLA, the company’s pivotal Phase 3 trial of relacorilant plus nab-paclitax
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom